Latest News Feed

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement
Press Release Mar 31, 2025
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

The equity financing is at a 10% premium to the market share price1
Press Release Dec 19, 2024
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment

  • This submission comes after successful INTERACT meeting with the FDA earlier this year.

  • NLS Pharmaceutics and Kadimastem working to close merger by the end of January 2025
Press Release Dec 11, 2024
NLS Pharmaceutics CEO Issues Letter to Shareholders
Press Release Dec 3, 2024
NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders
Press Release Nov 18, 2024
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement
Press Release Nov 4, 2024
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement
Press Release Oct 28, 2024
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements
Press Release Oct 21, 2024
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence
Press Release Oct 15, 2024
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules
Press Release Sep 25, 2024
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split
NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge
Press Release Jul 29, 2024
NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge

The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy platform

Each of Kadimastem and NLS Pharmaceutics has received commitments of support for the transaction from shareholders representing more than 40% of their respective outstanding shares
Press Release Jun 28, 2024
NLS Pharmaceutics Announces Registered Direct Offering
Press Release Jun 27, 2024
NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments
Press Release Jun 25, 2024
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements
Press Release Jun 11, 2024
NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)
Press Release May 28, 2024
NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model
Press Release May 24, 2024
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq
Press Release Apr 19, 2024
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
Press Release Mar 22, 2024
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
Press Release Mar 20, 2024
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
Press Release Mar 20, 2024
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
Press Release Mar 14, 2024
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
Press Release Mar 11, 2024
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
Press Release Feb 23, 2024
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
Notice of Deficiency with Nasdaq Continued Listing Requirements
Press Release Jan 12, 2024
Notice of Deficiency with Nasdaq Continued Listing Requirements
Press Release Dec 29, 2023
NLS Pharmaceutics CEO Issues Letter to Shareholders
Press Release Dec 1, 2023
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.
Press Release Nov 28, 2023
NLS Pharmaceutics Announces Election of Additional Board Members
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia
Press Release Nov 27, 2023
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia
Press Release Nov 16, 2023
NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan
Press Release Oct 25, 2023
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
Press Release Oct 19, 2023
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions
Press Release Oct 12, 2023
NLS Pharmaceutics Announces Company Update on Strategic Partnerships
NLS Pharmaceutics CEO Issues Letter to Shareholders
Press Release Aug 28, 2023
NLS Pharmaceutics CEO Issues Letter to Shareholders
Press Release Jul 3, 2023
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol
Press Release Jun 30, 2023
NLS Pharmaceutics Releases the Results from its Annual General Meeting
Press Release Jun 30, 2023
NLS Pharmaceutics Company Update and Webcast Today Postponed
Press Release Jun 19, 2023
CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Press Release Jun 19, 2023
NLS Pharmaceutics Announces Company Update Webcast
Press Release Jun 15, 2023
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
NLS Pharmaceutics Announces Company Update Webcast
Press Release Jun 15, 2023
NLS Pharmaceutics Announces Company Update Webcast
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol
Press Release Jun 14, 2023
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
Press Release May 8, 2023
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023
Press Release May 4, 2023
NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023
NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
Press Release May 2, 2023
NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology
Press Release Apr 25, 2023
NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology
NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2
Press Release Mar 27, 2023
NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2
NLS Pharmaceutics to Present at the 35th Annual Roth Conference
Press Release Mar 1, 2023
NLS Pharmaceutics to Present at the 35th Annual Roth Conference
NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
Press Release Jan 30, 2023
NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement
Press Release Jan 25, 2023
NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement